MedTrace Logo

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

NCT07451002 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 270

Last updated 2026-05-08

No results posted yet for this study

Summary

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.

Conditions

Sponsors & Collaborators

  • Janssen Cilag S.A.S.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag France Clinical Trial · Janssen-Cilag France

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-18
Primary Completion
2028-01-03
Completion
2028-01-03

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07451002 on ClinicalTrials.gov